Sign in

You're signed outSign in or to get full access.

Madeline

Research Analyst at William Blair

Madeline Welch is an Analyst who began her career as an investment banking intern at William Blair and BMO, focusing on a broad range of financial sectors. Although her current analyst role is at Slate Asset Management, she gained foundational experience at William Blair, contributing to projects for notable clients in investment banking. Madeline holds a Bachelor of Science in Finance from the Kelley School of Business at Indiana University and started her analyst position at Slate in 2024 as part of their Analyst Rotation Program. While still early in her career, she is building her credentials and experience across leading financial institutions, with professional licensing and performance data yet to be established.

Madeline's questions to INCYTE (INCY) leadership

Question · Q4 2025

Madeline Kern asked if pre-NDA discussions with the FDA for povorcitinib in HS included the potential to include biologic-naive patients in the labeled indication.

Answer

Steven Stein, CMO, confirmed that the povorcitinib HS study included both prebiologic and postbiologic populations, demonstrating activity in both. He reiterated strong HiSCR response rates, pain control, and draining tunnel data, and stated that Incyte is seeking a label that covers both patient populations.

Ask follow-up questions

Fintool

Fintool can predict INCYTE logo INCY's earnings beat/miss a week before the call

Question · Q4 2025

Madeline Kern asked about the pre-NDA discussions with the FDA regarding povorcitinib in hidradenitis suppurativa (HS), specifically whether the potential label would include biologic-naive patients.

Answer

Steven Stein, CMO, Incyte, confirmed that the povorcitinib HS study included both pre-biologic and post-biologic populations, demonstrating activity in both. He stated that Incyte is seeking a label that covers both patient populations.

Ask follow-up questions

Fintool

Fintool can write a report on INCYTE logo INCY's next earnings in your company's style and formatting

Madeline's questions to Autolus Therapeutics (AUTL) leadership

Question · Q3 2025

Madeline, on behalf of Matt Pips, asked for rough timelines for completing the pivotal cohort in pediatric ALL and the total market opportunity across both adult and pediatric ALL patients.

Answer

Dr. Christian Itin, CEO of Autolus Therapeutics, estimated the pediatric ALL market opportunity in the US and Europe to be around 1,000 patients, with a significant proportion in the high-risk category. He projected that the phase two portion of the pediatric study could enter the follow-up period in 2027, with data potentially available in late 2027 or early 2028.

Ask follow-up questions

Fintool

Fintool can predict Autolus Therapeutics logo AUTL's earnings beat/miss a week before the call